Clinical trials: Primary Light Chain (AL) Amyloidosis
Amyloidosis, Amyloid
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
- Conditions
- Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy
- Trial name
- MED-hATTR (NCT03431896)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The Cleveland Clinic
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
Primary Amyloidosis of Light Chain Type
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
The aim of the study is to evaluate the safety and efficacy of Pomalidomide and Dexamethasone in patients who did not achieve a complete response after initial treatment with both an alkylating agent (Melphalan or…
- Trial name
- NCT01510613
- Testing
- Pomalidomide and Dexamethasone
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Primary Systemic Amyloidosis
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis.
- Trial name
- DUAL (NCT02207556)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Primary Amyloidosis
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at…
- Trial name
- NCT01707264
- Testing
- NEOD001
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- Prothena Biosciences Ltd.
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Recurrent Primary Amyloidosis
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement.
- Trial name
- NCT03252600
- Testing
- Cyclophosphamide, Dexamethasone, Elotuzumab
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis.
- Trial name
- NCT01078454
- Testing
- melphalan, dexamethasone, bortezomib
- Where
- 209 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis.
- Conditions
- Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
- Trial name
- NCT03283917
- Testing
- Daratumumab, Dexamethasone, Ixazomib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00002810
- Testing
- filgrastim, melphalan, bone marrow ablation with stem cell support
- Where
- United States
- Sponsor
- Temple University
Primary Amyloidosis
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
The treatment with oral melphalan and prednisone has been recommended as standard treatment of AL amyloidosis but the results are rather disappointing.
- Trial name
- LEOMEX (NCT00883623)
- Testing
- Lenalidomide
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Amyloidosis
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
The purpose of this study is to determine the safety and activity of the combination of lenalidomide with intermediate dose dexamethasone and cyclophosphamide in patients with primary systemic (AL ) amyloidosis.
- Trial name
- NCT00981708
- Testing
- Lenalidomide, Dexamethasone and Cyclophosphamide
- Where
- Greece
- Volunteers
- 37 people
- Sponsor
- University of Athens
AL Amyloidosis (AL), t(11;14) Positive
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis.
- Trial name
- NCT07335887
- Testing
- sonrotoclax, Daratumumab, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking University People's Hospital
Primary Light Chain (AL) Amyloidosis
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory primary light chain (AL) amyloidosis.The primary objectives are to assess the safety of FKC289 and to establish the…
- Trial name
- NCT07765524
- Testing
- FKC289 infusion
- Where
- 11 sites in China
- Volunteers
- 32 people
- Sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
The purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan…
- Trial name
- NCT00458822
- Testing
- bortezomib, dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Kidney Disease, Acute Myeloid Leukemia (AML)
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor.
- Conditions
- Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)
- Trial name
- BMT (NCT01758042)
- Testing
- Haploidentical Bone Marrow/Kidney
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma and Plasma Cell Neoplasm
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients…
- Trial name
- NCT00003853
- Testing
- 4'-iodo-4'-deoxydoxorubicin
- Where
- 3 sites in United States, Italy
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Primary Systemic Amyloidosis
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Iododoxorubicin may dissolve protein deposits and be an effective treatment for primary systemic amyloidosis. Phase I trial to determine the effectiveness of iododoxorubicin in treating patients who have primary systemic…
- Trial name
- NCT00030381
- Testing
- 4'-iodo-4'-deoxydoxorubicin, pharmacological study
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Light Chain Deposition Disease, Primary Systemic Amyloidosis
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease.
- Trial name
- NCT01728259
- Testing
- pomalidomide, bortezomib, dexamethasone
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Giving melphalan and bortezomib before and after a stem cell transplant stops the growth of abnormal cells by stopping them from dividing or killing them.
- Trial name
- NCT00790647
- Testing
- filgrastim, bortezomib, melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center